Apple Heart Study: Assessment of Wristwatch-Based Photoplethysmography to Identify Cardiac Arrhythmias
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03335800 |
Recruitment Status :
Completed
First Posted : November 8, 2017
Results First Posted : March 30, 2020
Last Update Posted : March 30, 2020
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Atrial Fibrillation Arrhythmias, Cardiac Atrial Flutter | Device: Apple Heart Study App | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 419927 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Screening |
Official Title: | Apple Heart Study: Assessment of Wristwatch-Based Photoplethysmography to Identify Cardiac Arrhythmias |
Actual Study Start Date : | November 29, 2017 |
Actual Primary Completion Date : | February 21, 2019 |
Actual Study Completion Date : | February 21, 2019 |

Arm | Intervention/treatment |
---|---|
Experimental: Apple Heart Study App |
Device: Apple Heart Study App
The Apple Heart Study app is a mobile medical app that analyzes pulse rate data. The app identifies episodes of irregular heart rhythms consistent with atrial fibrillation and other arrhythmias. |
- Atrial Fibrillation (AF) of Greater Than 30 Seconds [ Time Frame: During ambulatory ECG monitoring (up to 8 days) ]Proportion of notified participants who received an irregular pulse notification and that had AF detected on the ambulatory ECG.
- Confirmed AF With a Detection by a Component of the App [ Time Frame: During ambulatory ECG monitoring (up to 8 days) ]Simultaneous ambulatory ECG monitoring indicating an irregular rhythm consistent with AF during time intervals when an app component (tachogram) is positive for an irregular pulse among those who received an irregular heartbeat notification.
- Concordant AF With App Algorithm Notification [ Time Frame: During ambulatory ECG monitoring (up to 8 days) ]Simultaneous ambulatory ECG monitoring indicating an irregular rhythm consistent with AF when the app based algorithm is positive for an irregular pulse among those who received a notification.
- Self-reported Contact With a Health Care Provider [ Time Frame: 90 days to 15 months ]Percentage of participant who self-reported contact with a health care provider within 90 days following an irregular pulse watch notification. Participants could self-report this health-care provider contact from 90 days following notification until the study survey went offline at end of study.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 22 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Possession of the following at time of eligibility screening, ascertained from automatic hardware/software/device pairing check:
- iPhone (5s or later) with iOS version 11.0 or later defined as iPhone model/iOS version used to complete screening eligibility.
- Apple Watch (Series 1 or later) with watchOS version 4.0 or later defined as Apple Watch model/watchOS paired with iPhone used to complete screening eligibility.
- Current resident of the United States at time of eligibility screening, defined by self-reported state of residence within the 50 states of the United States or District of Columbia.
- Proficient in written and spoken English, defined by self-report of comfort reading, writing, and speaking English on iPhone.
- Valid phone number associated with iPhone, ascertained from self-report.
- Valid email address, ascertained from self-report.
Exclusion Criteria:
- Self-reported diagnosis of Atrial Fibrillation.
- Self-reported diagnosis of Atrial Flutter.
- Currently on anti-coagulation therapy.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03335800
United States, California | |
Stanford University | |
Stanford, California, United States, 94304 |
Principal Investigator: | Minang (Mintu) Turakhia, MD, MAS | Stanford University | |
Principal Investigator: | Marco V. Perez, MD | Stanford University |
Documents provided by Minang (Mintu) Turakhia, Stanford University:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Minang (Mintu) Turakhia, Associate Professor of Medicine, Stanford University, Stanford University |
ClinicalTrials.gov Identifier: | NCT03335800 |
Other Study ID Numbers: |
1.0 |
First Posted: | November 8, 2017 Key Record Dates |
Results First Posted: | March 30, 2020 |
Last Update Posted: | March 30, 2020 |
Last Verified: | March 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | Yes |
Device Product Not Approved or Cleared by U.S. FDA: | Yes |
Product Manufactured in and Exported from the U.S.: | Yes |
Atrial Fibrillation Arrhythmias, Cardiac Atrial Flutter |
Heart Diseases Cardiovascular Diseases Pathologic Processes |